title: CDP-choline significantly restores phosphatidylcholine levels by differentially affecting phospholipase A2 and CTP: phosphocholine cytidylyltransferase after stroke.
abstract: Phosphatidylcholine (PtdCho) is a major membrane phospholipid, and its loss is sufficient in itself to induce cell death. PtdCho homeostasis is regulated by the balance between hydrolysis and synthesis. PtdCho is hydrolyzed by phospholipase A2 (PLA2), PtdChospecific phospholipase C (PtdCho-PLC), and phospholipase D (PLD). PtdCho synthesis is rate-limited by CTP:phosphocholine cytidylyltransferase (CCT), which makes CDP-choline. The final step of PtdCho synthesis is catalyzed by CDP-choline:1,2-diacylglycerol cholinephosphotransferase. PtdCho synthesis in the brain is predominantly through the CDP-choline pathway. Transient middle cerebral artery occlusion (tMCAO) significantly increased PLA2 activity, secretory PLA2 (sPLA2)-IIA mRNA and protein levels, PtdCho-PLC activity, and PLD2 protein expression following reperfusion. CDP-choline treatment significantly attenuated PLA2 activity, sPLA2-IIA mRNA and protein levels, and PtdCho-PLC activity, but did not affect PLD2 protein expression. tMCAO also resulted in loss of CCT activity and CCTalpha protein, which were partially restored by CDP-choline. No changes were observed in cytosolic PLA2 or calcium-independent PLA2 tMCAO. protein levels after Up-regulation of PLA2, PtdCho-PLC, and PLD and regulation of CCT collectively down-resulted in loss of PtdCho, which was significantly restored by CDP-choline treatment. CDP-choline treatment significantly attenuated the infarction volume by 55 +/- 5% after 1 h of tMCAO and 1 day of reperfusion. Taken together, these results suggest that CDP-choline significantly restores Ptd-Cho levels by differentially affecting sPLA2-IIA, PtdCho-PLC, and CCTalpha after transient focal cerebral ischemia. A hypothetical scheme is proposed integrating results from this study and from other reports in the literature.
authors.affiliation: Department of Neurological Surgery, University of Wisconsin, Madison, WI 53792-3232, USA. adibhatl@neurosurg.wisc.edu
authors.forename: Rao Muralikrishna
authors.initials: RM
authors.lastname: Adibhatla
authors.forename: James F
authors.initials: JF
authors.lastname: Hatcher
authors.forename: Eric C
authors.initials: EC
authors.lastname: Larsen
authors.forename: Xinzhi
authors.initials: X
authors.lastname: Chen
authors.forename: Dandan
authors.initials: D
authors.lastname: Sun
authors.forename: Francis H C
authors.initials: FH
authors.lastname: Tsao
mesh_terms: D000818:Animals; D002545:Brain Ischemia / Q000201:enzymology* / Q000378:metabolism; D019916:Choline-Phosphate Cytidylyltransferase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D003566:Cytidine Diphosphate Choline / Q000494:pharmacology*; D005786:Gene Expression Regulation / Q000502:physiology; D008297:Male; D010713:Phosphatidylcholines / Q000378:metabolism*; D010739:Phospholipase D / Q000096:biosynthesis / Q000235:genetics; D010741:Phospholipases A / Q000235:genetics / Q000378:metabolism*; D054467:Phospholipases A2; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D020303:Rats, Inbred Dahl; D017207:Rats, Sprague-Dawley
chemical_list: D010713:Phosphatidylcholines; D012333:RNA, Messenger; D003566:Cytidine Diphosphate Choline; D019916:Choline-Phosphate Cytidylyltransferase; D010741:Phospholipases A; D054467:Phospholipases A2; C105606:phospholipase D2; D010739:Phospholipase D